Why Shattuck Labs Stock Soared in December
A recommendation upgrade from an analyst at the beginning of December set the tone for Shattuck Labs (NASDAQ: STTK) stock in 2025's final month. The clinical-stage biotech's share price rose by almost 74% as a result.
The person responsible for that influential move was H.C. Wainwright's Joseph Pantginis, who on Dec. 1 shifted his recommendation on Shattuck to buy from his previous neutral. He set his new price target at $6 per share, which at the time was nearly three times the stock's level.
Image source: Getty Images.
Source Fool.com
